Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioGeneration Ventures (BGV) is a prominent venture capital firm founded in Naarden, Netherlands, specializing in early-stage funding for innovative life sciences companies. Established as part of the Forbion-BGV platform, which includes Forbion Ventures and Forbion Growth, BGV has carved a niche in the biotechnology sector. The firm primarily acts as a lead investor, focusing on seed investments in biotechnology companies that address significant unmet medical needs. With over €100 million in funds under management, BGV demonstrates a robust capacity for investment in early-stage life sciences ventures.
BGV's strategic approach involves collaboration with other professional investors and the establishment of partnerships with academic institutions and healthcare companies across Europe and North America. This collaborative model enhances their investment strategy, allowing them to support the formation of companies and provide essential funding during the seed, Series A, and Series B stages. The firm is recognized for its commitment to fostering innovation in biotechnology, leveraging its extensive network to identify and nurture promising startups.
BGV's investment focus is centered on early-stage life sciences companies, particularly within the biotechnology sector. The firm seeks to invest in companies that are pioneering innovative solutions to address high unmet medical needs. BGV's investment strategy encompasses a range of activities, including company formation, seed funding, and support for subsequent funding rounds such as Series A and B. This comprehensive approach allows BGV to play a pivotal role in the growth and development of its portfolio companies.
In addition to financial support, BGV emphasizes the importance of strategic partnerships. The firm collaborates with other investors and has established connections with academic institutions and healthcare companies in the Netherlands, the EU, and the US. This network not only enhances BGV's investment capabilities but also provides portfolio companies with access to valuable resources, expertise, and market insights. BGV is particularly interested in companies that are developing groundbreaking therapies and technologies that can significantly impact patient care and outcomes.
BGV boasts a notable portfolio of companies that exemplify its commitment to advancing biotechnology. One of its most significant successes is **Acerta Pharma**, co-founded by BGV, which developed Calquence® (acalabrutinib), a drug approved by the FDA for treating hematologic malignancies. Acerta Pharma was sold to AstraZeneca for up to $7 billion in 2016, marking a landmark exit for BGV.
Other prominent portfolio companies include **Catalym**, which focuses on developing antibodies against a placental factor overexpressed in various tumor types; **Epsilogen**, a pioneer in new antibody therapeutics in oncology; **Genase Therapeutics**, which is developing a small molecule inhibitor targeting a metabolic pathway; and **NorthSea Therapeutics**, which works on structurally engineered fatty acids for treating metabolic diseases. These companies reflect BGV's strategic focus on innovative therapeutic solutions that address critical medical needs.
To pitch BGV, founders should visit their website at biogenerationventures.com or email them at info@biogeneration.vc. They prefer pitches that clearly articulate the innovative aspects of the business and its potential to address unmet medical needs.
BGV invests in early-stage companies, specifically focusing on seed, Series A, and Series B funding rounds. This allows them to support startups from their inception through to more advanced stages of development.
Founders can pitch BGV by visiting their website at biogenerationventures.com or by emailing them directly at info@biogeneration.vc. BGV welcomes pitches that clearly outline the innovative aspects of the business and its potential to address unmet medical needs.
BGV primarily focuses on the biotechnology sector within the life sciences. They are particularly interested in companies that are developing innovative solutions to address high unmet medical needs.
While specific check sizes are not disclosed, BGV manages over €100 million in funds, indicating a significant capacity to support early-stage investments in biotechnology companies.
BGV invests in companies located in Europe and North America. They have established strategic partnerships with various stakeholders in these regions to enhance their investment strategy.
BGV provides not only financial support but also strategic guidance and access to their extensive network of industry contacts, which can be invaluable for startups navigating the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.